Breast cancer precision prevention

What is breast cancer precision prevention?

Breast cancer precision prevention is a modern personalized approach to breast cancer prevention that includes:

  • Assessment of a woman’s polygenic risk for breast cancer. Polygenic risk is the strongest independent risk factor for breast cancer.
  • Personalized medical recommendations for additional screening and preventive procedures and health behaviors according to individual risk level.
  • Specification of the need for additional monogenic testing based on family history. Recommendations for additional genetic testing if necessary.
  • Medical report as a referral for personalized prevention, if indicated.

Why is breast cancer precision prevention necessary?

Breast cancer precision prevention is necessary to prevent deaths from breast cancer.

Breast cancer is the most common malignancy among women – every 8th woman in Europe develops breast cancer (1). Currently, an average of 230 women die from breast cancer in Europe every day (2).

Breast cancer death is avoidable by using precision prevention assets (3, 4, 5).

Who needs breast cancer precision prevention?

Breast cancer precision screening is for all women aged 30-75.

How to get breast cancer precision prevention?

  1. The first step is to evaluate the personal polygenic risk for breast cancer. For this, you can order the AnteBC test. Polygenic risk is the strongest independent risk factor for breast cancer, and its assessment is the basis for precision prevention.
  2. The result of the AnteBC genetic test is a medical report with risk assessments and precise recommendations, at what age, and how to take preventive actions. The test results can be accessed in our patient portal MyAntegenes.
  3. Complete a questionnaire to assess the need for additional testing for rare single gene variants for breast cancer. The questionnaire follows the recommendations made by medical professionals, based on which the corresponding single gene tests are currently prescribed.
  4. If testing of rare single gene variants for breast cancer is indicated, we recommend that you consult your local medical geneticist for this purpose.
  5. If there is an indication according to AnteBC test recommendations, you can use the AnteBC test report and refer to breast clinics or your family physician for recommended screening and prevention activities.

How do you get the results?

The result of the test is a medical report which is securely sent to the patient. The report can be used also by the patient’s physician.

Start breast cancer precision prevention

Testing is easy - you can order the test kit online.


Genetic risk test for breast cancer

  • Includes 2803 genetic breast cancer variants
  • Breast cancer risk assessment with medical recommendations

Recommended for women aged 30–75.

The test results provide answers to the following questions:
• What is my genetic risk level for breast cancer?
• At what age should I start breast cancer screening?
• Should I take additional measures to prevent breast cancer?
• What can I do to reduce my risk of breast cancer?
• What changes and symptoms do I need to look out for regarding breast cancer?

Additional information

Antegenes is an European Union Medical Laboratory, licence: L05386.
All services offered are official European cross-border healthcare services.

Antegenes’ tests are scientifically validated using UK Biobank and Estonian Biobank data.
All tests are registered as CE-marked in vitro medical devices. AnteBC is registered as a CE-marked medical device (in vitro diagnostics, IVD) in the Estonian Medical Devices Database (EMDDB code: 14726), the EUDAMED database (UDI-DI: 04745010362019), and the UK MHRA Registry (GMDN code: 59918).


  1. Curado Be MP, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. Cancer Incidence in Five Continents Volume IX. WHO Press (Lyon, France). 2007.
  2. OECD/European Union (2022) HaaGESoHitEC, OECD Publishing, Paris,
  3. Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, et al. Benefits and Harms of Breast Cancer Screening. Jama. 2015.
  4. Uk I, Cancer B. The benefits and harms of breast cancer screening: an independent review. Lancet (London, England). 2012.
  5. Tabár L, Dean PB, Chen TH-H, Yen AM-F, Chen SL-S, Fann JC-Y, et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer. 2018.